

Q-linea announces the sale of warrants of series TO 1 from Nexttobe AB to Investment AB Öresund

Q-linea AB (publ) ("Q-linea" or the "Company") (Nasdaq Stockholm: QLINEA), has received information from the Company's shareholder Nexttobe AB ("Nexttobe") that they have completed a sale of all held warrants of series TO 1 ("warrants") to Investment AB Öresund ("Öresund"), which has undertaken, under certain conditions, to utilize these warrants for subscription of new ordinary shares.

Stuart Gander, CEO in Q-linea, comments:

"We are very glad that Öresund has shown a strong interest to increase their shareholding and engagement in Q-linea. Doing this through the warrants is also beneficial for Q-linea, as it will increase the likelihood of a successful warrant programme in May 2025 and directly support the Company's capital needs."

On 5 November 2024, Q-linea announced that the board of directors had resolved on a rights issue of up to approximately SEK 225 million, which subsequently was approved by the extraordinary general meeting on 6 December 2024. Four (4) unit rights entitled the holder to subscribe for one (1) Unit, where each Unit consists of two (2) ordinary shares and one (1) warrant of series TO1 free of charge.

Each warrant of series TO1 entitles the holder to subscribe for one (1) new ordinary share in Q-linea during the period from 5 May 2025 up to and including 19 May 2025. The exercise price for the warrants corresponds to 70 percent of the volume-weighted average price of the Company's share on Nasdaq Stockholm during the period from 14 April 2025 up to and including 29 April 2025, however not lower than the share's quota value.

Q-linea's operations may, upon assessment, be considered to conduct protected activities according to the Act (2023:560) on the Review of Foreign Direct Investments. Consequently, an investment in shares through the exercise of the warrants that results in an investor acquiring a shareholding equivalent to or exceeding certain thresholds of the total number of votes in the Company after the exercise of the warrants must be reported to the Inspectorate for Strategic Products ("ISP") before the investment can be carried out. The investment may not be executed until the Inspectorate for Strategic Products has either taken no action on the notification or approved the investment.

Q-linea has received information from the Company's shareholder Nexttobe AB that they have completed a sale of all warrants held, corresponding to 500,000,000 warrants, to Öresund. In connection with the acquisition, Öresund has undertaken to exercise all acquired warrants provided that Öresund receives approval from ISP and that the warrants are so-called "in-the-money", i.e. that the subscription price is below the current share price, during the entire exercise period, from 5 May 2025 up to and including 19 May 2025.

For more information, please contact:

Erika Kjellberg Eriksson, CEO and Chair of the Board, Nexttobe
Erika.Kjellberg@nxt2b.com

Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
+1 857 409 7463

Christer Samuelsson, CFO /IR, Q-linea AB
Christer.Samuelsson@qlinea.com
+46 (0) 70-600 15 20

About Q-linea

Q-linea's rapid AST system, ASTar[®], accelerates and simplifies the time-sensitive workflows faced during the treatment of patients with bloodstream infections and sepsis. Hospitals use ASTar to vastly reduce the time to optimal antimicrobial therapies and ensure that patients receive the correct treatments sooner — when time matters most. We are helping to create sustainable healthcare, now and in the future, and safeguard the effectiveness of antibiotics for generations to come.

Q-linea is headquartered in Uppsala, Sweden and has regional offices in Italy and the USA, with partnerships worldwide.

ASTar Instrument and ASTar BC G- Consumable kit are CE-IVD marked and FDA 510(k) cleared. For more information, please visit www.qlinea.com

Attachments

[Q-linea announces the sale of warrants of series TO 1 from Nexttobe AB to Investment AB Öresund](#)